Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)-Reference-Cited by-同舟云学术

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)

Published:2014-11 Issue:11 Volume:2 Page:902-910
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

McKone Edward F,Borowitz Drucy,Drevinek Pavel,Griese Matthias,Konstan Michael W,Wainwright Claire,Ratjen Felix,Sermet-Gaudelus Isabelle,Plant Barry,Munck Anne,Jiang Ying,Gilmartin Geoffrey,Davies Jane C

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference29 articles.

1. Cystic fibrosis;Cutting,2012

2. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study;McKone;Lancet,2003

3. Cystic Fibrosis Foundation. Patient Registry 2012 Annual Data Report, Bethesda, MD, USA; 2013.

4. ECFS Patient Registry Annual Data Report 2008–09, 2012.

5. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening;Bobadilla;Hum Mutat,2002

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology of advanced cystic fibrosis lung disease in the modulator era;Current Opinion in Pulmonary Medicine;2024-08-23

2. Ageing and ivacaftor: unravelling the long-term effects;Thorax;2024-08-06

3. Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: A follow-up study;Nutrition;2024-07

4. Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor;Journal of Cystic Fibrosis;2024-07

5. Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis;Thorax;2024-06-27